A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies
ABSTRACT Background Temsirolimus is an mTOR antagonist with proven anticancer efficacy. Preclinical data suggest greater anticancer effect when mTOR inhibitors are combined with cytotoxic chemotherapy. We performed a Phase I assessment of the combination of temsirolimus and capecitabine in patients...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Wiley
2021-03-01
|
| Rangatū: | Cancer Medicine |
| Ngā marau: | |
| Urunga tuihono: | https://doi.org/10.1002/cam4.3672 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|